[HTML][HTML] Identification of a physiologically relevant endogenous ligand for PPARα in liver

MV Chakravarthy, IJ Lodhi, L Yin, RRV Malapaka… - Cell, 2009 - cell.com
MV Chakravarthy, IJ Lodhi, L Yin, RRV Malapaka, HE Xu, J Turk, CF Semenkovich
Cell, 2009cell.com
The nuclear receptor PPARα is activated by drugs to treat human disorders of lipid
metabolism. Its endogenous ligand is unknown. PPARα-dependent gene expression is
impaired with inactivation of fatty acid synthase (FAS), suggesting that FAS is involved in
generation of a PPARα ligand. Here we demonstrate the FAS-dependent presence of a
phospholipid bound to PPARα isolated from mouse liver. Binding was increased under
conditions that induce FAS activity and displaced by systemic injection of a PPARα agonist …
Summary
The nuclear receptor PPARα is activated by drugs to treat human disorders of lipid metabolism. Its endogenous ligand is unknown. PPARα-dependent gene expression is impaired with inactivation of fatty acid synthase (FAS), suggesting that FAS is involved in generation of a PPARα ligand. Here we demonstrate the FAS-dependent presence of a phospholipid bound to PPARα isolated from mouse liver. Binding was increased under conditions that induce FAS activity and displaced by systemic injection of a PPARα agonist. Mass spectrometry identified the species as 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Knockdown of Cept1, required for phosphatidylcholine synthesis, suppressed PPARα-dependent gene expression. Interaction of 16:0/18:1-GPC with the PPARα ligand-binding domain and coactivator peptide motifs was comparable to PPARα agonists, but interactions with PPARδ were weak and none were detected with PPARγ. Portal vein infusion of 16:0/18:1-GPC induced PPARα-dependent gene expression and decreased hepatic steatosis. These data suggest that 16:0/18:1-GPC is a physiologically relevant endogenous PPARα ligand.
cell.com